Alligator Bioscience (ATORX) Q1 2026 earnings summary

Executive summary

• Final phase II data for mitazalimab in first-line metastatic pancreatic cancer presented, showing promising efficacy and survival benefits, supporting advancement to registrational phase III trials, with final OPTIMIZE-1 data and mechanistic insights presented at major meetings.

• Letter of intent signed with Unicancer to explore an investigator-sponsored phase III study for mitazalimab, aiming to reduce trial costs while maintaining regulatory quality.

• Ongoing partnering discussions and strategic focus on combination therapies, particularly with KRAS inhibitors, as the treatment landscape evolves.

• HLX22, a partnered HER2 antibody, continues clinical progress with phase II/III trials in breast and gastric cancer, offering potential long-term financial upside and milestone/royalty income.

• Strengthened IP position for RUBY bispecific antibody technology.

Financial highlights

• Q1 operating costs were approximately SEK 17 million, mainly general expenses with limited initial phase III costs, and R&D costs represented 54% of operating costs.

• Cash position at quarter-end was SEK 33 million, providing runway into mid-Q3 2026.

• TO 14 warrants exercised at a 38% rate, raising SEK 90 million in gross proceeds, with SEK 19 million reported as gross proceeds in another source.

• Net sales for Q1 2026 were SEK 0.5 million, down from SEK 1.4 million in Q1 2025.

• Operating loss narrowed to SEK -17.8 million from SEK -43.7 million year-over-year.

Outlook and guidance

• Phase III feasibility assessment for mitazalimab ongoing, with trial initiation targeted for Q4 2026, pending regulatory and contractual finalization.

• Exploring various financing options to support ongoing operations and phase III trial costs, including licensing, grants, and additional capital raising.

• Additional randomized phase II trial in biliary tract cancer planned for 2026.

• Focus remains on advancing mitazalimab to registrational development and preserving HLX22 value without incurring development costs.

• Ongoing partnering discussions and cost-aware execution to support future development.